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Abstract
Mycobacterium tuberculosis (Mtb) is particularly challenging for the immune system
being an intracellular pathogen, and a variety of T cell subpopulations are
activated by the host defence mechanism. In this study, we investigated T cell
responses and regulation in active TB patients with drug-sensitive Mtb (N = 18)
during 24 weeks of efficient anti-TB therapy. T cell activation, differentiation,
regulatory T cell (Treg) subsets, Mtb-induced T cell proliferation and in vitro IL-
10 and TGF-b modulation were analysed by flow cytometry at baseline and after
8 and 24 weeks of therapy, while soluble cytokines in culture supernatants were
analysed by a 9-plex Luminex assay. Successful treatment resulted in significantly
reduced co-expression of HLA-DR/CD38 and PD-1/CD38 on both CD4+ and
CD8+ T cells, while the fraction of CD4+CD25highCD127low Tregs (P = 0.017)
and CD4+CD25highCD127low CD147+ Tregs (P = 0.029) showed significant
transient increase at week 8. In vitro blockade of IL-10/TGF-b upon Mtb
antigen stimulation significantly lowered the fraction of ESAT-6-specific
CD4+CD25highCD127low Tregs at baseline (P = 0.047), while T cell prolifer-
ation and cytokine production were unaffected. Phenotypical and Mtb-specific T
cell signatures may serve as markers of effective therapy, while the IL-10/TGF-b
pathway could be a target for early inhibition to facilitate Mtb clearance.
However, larger clinical studies are needed for verification before concluding.
Introduction
Tuberculosis (TB) remains one of the world’s most lethal
communicable diseases. In 2014, 1.5 million people died
from the disease, 400,000 of whom were HIV-infected [1].
Although nearly one-third of the world’s population is
infected with Mycobacterium tuberculosis (Mtb), the majority
do not develop TB disease. Key immunological mecha-
nisms are responsible for both tissue protection and damage
[2]. Thus, stage of infection as well as extent and outcome
of TB disease depend on the balance between immune
stimulation and immune suppression.
In murine models, it is well established that CD4+ and
CD8+ T cell reactivity to Mtb antigens, with production of
interferon gamma (INF-c) and tumour necrosis factor alpha
(TNF-a), is essential for TB protection [3–5]. The
importance of Th1-mediated immunity is also demon-
strated in humans [6, 7] and further evidenced by the
increased risk of developing active TB in patient treated
with TNF-a blockers and in HIV infection with impaired
cellular immunity [8, 9]. However, immune regulation and
recovery during anti-TB treatment have not been fully
elucidated; some report restoration of in vitro Mtb antigen-
induced T cell proliferation and INF-c responses [10],
whereas we and others have demonstrated an initial decline
in Mtb-specific IFN-c-producing T cells without full
immune recovery of cytokine profiles during effective
chemotherapy [11, 12].
Cytokines play an important role in the host immune
response as both effectors and regulators of Mtb immunity,
in innate defence against Mtb infection and in determining
the subsequent adaptive T cell responses [13]. A shift in
cytokine production could influence restoration of cellular
responses. Interleukin 10 (IL-10) and transforming growth
factor b (TGF-b) both suppress the activation of Th1 cells,
and corresponding cytokines are elevated in patients with
active TB and decrease during treatment [14–18]. Also,
regulatory T cells (Tregs), cells that are critical in the
maintenance of immune tolerance, are thought to suppress
efficient protective immune responses against the pathogen
hindering its effective clearance [19, 20]. Treg levels are
found elevated in active TB [21, 22] and decline during
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treatment [23, 24]. However, data describing Treg
dynamics during the course of treatment are conflicting
and need further analysis [12, 25].
Hence, this explorative study was designed to assess T
cell responses and regulation in terms of Mtb-specific
activation, proliferation and cytokine production in
patients with TB during the course of efficient anti-TB
therapy. Also, the study aimed to explore functional
regulation of Mtb-specific proliferative responses and
in vitro expanded Tregs by targeting the IL-10/TGF-b
pathway.
Materials and methods
Study participants. Patients with active TB infection were
recruited from the Department of Infectious Diseases, Oslo
University Hospital, Norway, and followed longitudinally
during 24 weeks of anti-TB chemotherapy. Demographical
and clinical data were as described in Table 1. Two
patients were native Norwegians (age 81 and 92), and the
remaining were immigrants, predominantly from Africa
(N = 9) and Asia (N = 6). Patients were categorized into
pulmonary TB (PTB, N = 10) or extra pulmonary TB
(EPTB, N = 8). All subjects were culture positive with
drug-sensitive TB, HIV-uninfected, and treated with a
standard TB treatment of rifampicin, isoniazid, ethambutol
and pyrazinamide for 2 months followed by additional
treatment with rifampicin and isoniazid. All patients
responded to treatment, PTB patient with sputum
conversion and culture clearing, whereas patients with
EPTB demonstrated clinical improvement and normaliza-
tion of inflammation parameters. Blood samples were
obtained before and after 8 and 24 weeks of treatment. The
study was approved by the Norwegian Regional Ethics
Committee South East, and written informed consent was
obtained from all participants.
Cell separation and preparation. Peripheral blood mononu-
clear cells (PBMC) were isolated with cell preparation tubes
(CPTTM; Becton Dickinson (BD) Bioscience, San Jose, CA,
USA) with sodium heparin, cryopreserved in 90% fetal calf
serum (FCS; Sigma, St. Louis, MO, USA) and 10%
dimethylsulphoxide and stored at 145 °C until analysis.
After thawing, cells were rested overnight at 37 °C and 5%
CO2. Only samples with viability >85% were analysed.
Flow cytometry analysis. All flow cytometry data were
acquired using a BD FACS Canto II
TM
flow cytometer with
FACS DIVA software v 6.1 and analysed using Win List
6.0 (Verity Software House, Topsham, ME, USA) or FLOW
JO (Version 10; TreeStar Inc., Ashland, OR, USA).
Lymphocytes were gated by morphological parameters
(forward and side scatter).
Phenotypic T cell analysis. Phenotypic analysis of
PBMC was performed ex vivo after overnight rest in
unstimulated samples. After washing with serum-free
culture medium (Gibco, AIM V, Invitrogen/Life technolo-
gies, San Diego, CA, USA), pellets were resuspended and
incubated in the dark for 30 min with the appropriate
amount of the following monoclonal antibodies (mAbs):
CD3-Pacific Blue, CD4-AmCyan, HLA-DR-FITC, PD-1-
APC, CD38-PE, CCR7 PE-Cy7, CD27-Alexa Fluor 700,
CD45RA- PerCP-Cy5.5, CD25-PerCP-Cy5.5, CD147-
FITC, CD39-APC, CD161-PE (all BD Biosciences) and
CD127-PE-Cy7 (eBioscience, San Diego, CA, USA). CD4
and CD8 positive T cells (i.e. CD3+CD4) were gated to
PD1, CD38 and HLA-DR, respectively, and then Boolean
gating strategy was used to create surface marker combi-
nations. Various Treg phenotypes were defined as the
following: CD4+CD25highCD127low, CD4+CD25high
CD127lowCD161+, CD4+CD25highCD127lowCD39+ and
CD4+CD25highCD127low CD147+. T cell differentiation
was defined as CD45RA+CCR7+CD27+ (na€ıve cells),
CD45RA-CCR7-CD27+ (effector memory cells) and
CD45RA-CCR7+CD27+ (central memory cells). The neg-
ative control cells were stained with all the fluorescents
minus the ones in question. A representative gating
strategy for selected surface markers is shown in Fig. S1.
T cell proliferation assay. PBMCs (250,000 in 200 ll
AIM) were pulse labelled with carboxyfluorescein succin-
imidyl ester (CFSE) (Invitrogen Molecular Probes, Eugene,
OR, USA) at 2 lM for 5 min before stimulation in sterile
condition with peptide pools [Mtb-derived 6-kDa early
secretory antigenic target (ESAT-6) and 10-kDa culture
filtrate protein-10 (CFP-10), both 15-mer overlapping by
six amino acids peptide pools, >80% purity (Schafer,
Copenhagen, Denmark) at a final concentration of 1.5
lg/ml] alone, peptide pools with inhibitory mAbs to IL-10
(MAB217 Clone 23738) and TGF-b (MAB1837 Clone
1D11) at 10 lg/ml final concentration (both R&D Systems
Europe, Abingdon, UK), Staphylococcal Enterotoxin B
(SEB) (Sigma-Aldrich, Oslo, Norway) at 0.5 lg/ml as
positive control and serum-free culture medium as negative
test control (background proliferation) and cultured at
37°C and 5% CO2 in 96-well tissue culture plates (Nunc,
Roskilde, Denmark) for 6 days. Cell supernatants from
Table 1 Demographical and clinical characteristics of study participants
(N = 18).
Age median years (range) 33 (21–92)








ESR median mm/h (range)b 46 (6–101)
Culture positive (%) 18 (100)
aLymph node, pericard, abdominal, abscess, osteomyelitis
bErythrocyte sedimentation rate
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ESAT-6- and CFP-10-stimulated wells with and without
inhibitory mAbs to IL-10/TGF-b were harvested after 20 h
(100 ll) and kept at 80°C until required for multiplex
analyses. Cells were harvested after 6 days and stained with
CD3 Pacific Blue, CD4 AmCyan, CD25 PE, HLA-DR
APC (all BD Biosciences), CD127 Pe-Cy7 (eBioscience)
and 7-Aminoactinomycin (7-AAD) (BD Biosciences) to
exclude nonviable cells.
Mtb Ag-specific proliferative T cell responses were
defined as percentages of live (7AAD) CFSEdimCD3+ in
the CD4+ or CD8+ (i.e. CD4) population. Net prolifer-
ative responses were calculated by subtracting background
proliferation in corresponding unstimulated control cul-
tures. The cut-off for proliferation (CFSEdim) was set by the
median fluorescence intensity equal to or below the second
proliferated generation. T regulatory cells were analysed in
6 days cultures and defined as CD4+CD25highCD127dim
T cells.
An exploratory assessment of Mtb antigen-induced
regulation mediated by IL-10/TGF-b was defined as the
difference in 6-day proliferative responses with or
without the presence of IL-10/TGF-b blocking mAbs
above background proliferation as described elsewhere
[26].
Multiplex assay. The levels of IL-1b, IL-8, IL-10, IFN-c,
interferon gamma inducible protein 10 (IP-10), monocyte
chemotactic protein-1 (MCP-1), macrophage inflammatory
protein-1 (MIP-1), RANTES and TNF-a were measured in
supernatants from Mtb antigen-stimulated and inhibitory
IL-10/TGF-b cell cultures using Bio-Plex XMap technol-
ogy with a Luminex IS 100 instrument (Bio-Rad,
Hercules, CA, USA) and BIO-PLEX MANAGER Software v6
(Bio-Rad, Hercules, CA, USA). The STATLIA software
package v3 (Brendan Scientific Inc., Carlsbad, CA, USA)
was used to calculate sample cytokine concentrations. The
limit of detection was calculated as the concentration of
analyte on the standard curve for which the corresponding
MFI value is two standard deviations above the background
measured in the blank. IFN-c was below the lower
detection level (LDL) or detected at very low levels in
many samples (<80% below the LDL of the assay) and
excluded from further statistical analysis. Remaining
occasional values (<20%) below the LDL were replaced
by a defined common value (0.001), which allowed
nonparametric statistical analysis. To calculate Mtb-specific
levels of cytokines and chemokines, background responses
from unstimulated cell culture supernatants were sub-
tracted.
Statistics. Statistical analysis and graphics were per-
formed using GRAPHPAD PRISM v5.04 software (GraphPad,
San Diego, CA, USA). Nonparametrical statistical methods
were applied. Group-wise comparison was analysed by the
Mann–Whitney U-test, while dependent variables were
analysed by the two-tailed Wilcoxon matched-pair test.
Correlations were assessed using Spearman’s rank. P-values
<0.05 were considered significant. All patients were
included and analysed at all time points. However, some
data were excluded on criteria such as viability <85%, less
than 10,000 events in the lymphocyte gate and lack of SEB
responses prior to statistical calculations, hence leading to
different number of patient samples included in the
different subanalysis (Fig. 1).
Results
Changes in T cell activation during TB therapy
T cell activation, differentiation and senescence were
longitudinally evaluated on PBMC by surface expression
of the activation markers HLA-DR and CD38, na€ıve and
memory markers and programmed death protein (PD-1).
The co-expression of HLA-DR/CD38, indicating activated
T cell subsets, decreased after 8 weeks of effective treat-
ment for the CD4+ T cells (P = 0.032) and after 24 weeks
for the CD8+ T cells (P = 0.042) (Fig. 2A,B). Similarly,
an early decrease in co-expression of PD1/CD38 was
observed for the CD4+ T cells (P = 0.004) at week 8 and
later at week 24 also for the CD8+ T cell subsets
(P = 0.013) (Fig. 2C,D). In contrast, the fractions of
na€ıve, effector memory and central memory T cells did not
change during the treatment period, nor did stratification
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Figure 1 Patients included in the study. All patients samples included
were analysed at all time points. Samples were excluded from further
statistical analysis due to *lack of SEB response (N = 1) and viability <85%
(N = 1), **less than 10,000 events in the CD3+ lymphocyte gate (N = 4)
and technical problems (N = 1). SEB, Staphylococcal Enterotoxin B.
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Mtb-specific T cell proliferative responses and soluble markers
during anti-TB therapy
Themedian level ofMtb-specific proliferating CD4+ T cells in
the 6-day CFSE assay decreased transiently from baseline to
week 8, but significantly so only in the ESAT-6-stimulated
cells [median: 4.6% IQR (1.5–11.2) versus 2.4% (0.5–6.6),
P = 0.026] (Fig. 3A). No significant changes were observed
for the CFP-10-stimulated CD4+ T cells (Fig. 3B) or CD8+
T cells in response to any of the two antigens (Fig. 3C,D).
Also, levels of IL-1b, IL-8, IL-10, IP-10, MCP-1, MIP-1,
RANTES and TNF-a in cell culture supernatants upon 20 h
ofMtbAg stimulation did not change significantly during the
treatment period (data not shown). It should be noted that
proliferative responses as well as cytokine and chemokine
production were similar in subjects with PTB and EPTB.
In vitro IL-10/TGF-b-induced modulation of TB-specific T cell
responses
When functional effects upon T cell proliferation during
Mtb antigen stimulation mediated by TGF-b and IL-10
was assessed throughout anti-TB therapy, no significant
changes were detected at any time point (Fig. 3). More-
over, no significant changes were mediated by the two
inhibitory cytokines on the release of the selected
chemokines and cytokines after 20 h of Mtb antigen
stimulation (data not shown).
Changes of CD25highCD127low Tregs and explorative Treg
subsets during TB treatment
Phenotypic ex vivo analysis of Tregs in blood revealed a
transient increase in the fraction of CD4+CD25highC-
D127low Tregs after 8 weeks of therapy (P = 0.029)
followed by a significant decrease at week 24 (P = 0.048)
(Fig. 4A). A similar pattern was also observed in the
fraction of CD4+CD25highCD127lowCD147+ cells with a
significant increase from baseline to week 8 (P = 0.017)
followed by a modest decrease at week 24 (P = 0.015)
(Fig. 4B). In contrast, no statistical significant changes
were seen for the CD39+ (Fig. 4C) or the CD161+ Treg
subsets (Fig. 4D). Stratification of patients in PTB versus
EPTB did not alter the results (data not shown).
We next investigated changes in Tregs in vitro after
6-day stimulation by Mtb antigens. The fraction of
CD4+CD25highCD127low Tregs increased significantly by
Mtb antigen stimulation compared to the unstimulated
cells both at week 0 (P = 0.002) and 24 (P = 0.012)
(Fig. 5A). When Tregs were quantified in parallel cultures
that in addition provided functional blockade of the
inhibitory cytokines TGF-b and IL-10, this Treg subset
decreased significantly (P = 0.047) at baseline but not
during therapy (Fig. 5B).
Discussion
In this study, we present data on T cell responses and
regulation during the course of effective anti-TB treat-
ment. We show that levels of T cell activation declined,
while the fraction of Treg subsets displayed an early
increase with a subsequent decline to baseline levels in
response to 24 weeks of anti-TB therapy. In vitro blockade
of IL-10 and TGF-b inhibited the expansion ofMtb-specific
Tregs seen in untreated TB infection. Still, Mtb-specific
proliferative responses remained unaltered during therapy
with no further effect seen neither on proliferation nor on
Tregs when blocking the inhibitory cytokines.
Overall we found decreasing levels of CD38 and HLA-
DR in both CD4+ and CD8+ T lymphocytes during TB
treatment. These are markers that reflect T cell activation
in response to different pathogens [27, 28] and are found
to be elevated in patients with TB compared to subjects
with latent TB or uninfected controls [21, 29, 30]. Our
findings indicate a decrease in immune activation
throughout effective TB therapy that might mirror
reduced levels of bacterial burden. Our data also support
Figure 2 Activation and senescence markers. T cell expression of
different cell surface markers on directly stained peripheral blood
mononuclear cells from patients with active TB during 24 weeks of
effective anti-TB chemotherapy at baseline, week 8 and week 24.
Percentage of (A) CD4+HLA-DR+CD38+ (N = 13) (B) CD8+
(CD3+CD4) HLA-DR+CD38+ (N = 13) (C) CD4+PD-1+CD38+
(N = 14) and (D) CD8+(CD3+CD4) PD-1+CD38+ (N = 14) T cells.
Scatter dot plots are shown with median and interquartile range. P-values
were calculated by Wilcoxon’s matched-pairs test.
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a recent study concluding that activated HLA-DR+ CD4+
T cells are associated with increased TB disease risk both
in adolescence and BCG-vaccinated infants [31]. In
addition, we found decreasing levels of PD-1 expression
on both T cell subsets, most prominent at the end of
treatment. PD-1 is a co-inhibitory receptor that is
Figure 3 Mtb-specific proliferation during TB treatment. Six days proliferating T cells culture from patients with TB (N = 16) before and after 8 and
24 weeks of TB treatment with (triangles) or without (dots) inhibitory mAbs to IL-10/TGF-b. Percentage of (A) ESAT-6-stimulated CD4+ (B) CFP-10-
stimulated CD4+ and (C) ESAT-6-stimulated CD8+ (D) CFP-10-stimulated CD8+ T cells. Net proliferative responses calculated by subtracting
background proliferation in corresponding unstimulated controls. Scatter dot plots are shown with median and interquartile range. P-values were
calculated by Wilcoxon’s matched-pairs test.
Figure 4 Dynamic changes of Tregs during TB treatment. The fraction of different subsets of T regulatory cells in patients with TB (N = 15) before and
after 8 and 24 weeks of TB treatment in directly stained peripheral blood mononuclear cells in (A) CD4+CD25highCD127low, (B)
CD4+CD25highCD127lowCD147+, (C) CD4+CD25highCD127lowCD39+ and (D) CD4+CD25highCD127lowCD161+ T cells. Scatter dot plots are shown
with median and interquartile range (IQR). P-values were calculated by Wilcoxon’s matched-pairs test for dependent variables.
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upregulated on activated antigen-specific effector cells
[32]. PD-1 and its ligands are exploited by a variety of
micro-organisms to attenuate antimicrobial immunity and
hence may facilitate chronic infection [33]. In TB
infection, PD-1 is suggested to have a key regulatory
role during the immune response of the host to the
pathogen [34–36] and is expressed at higher levels in
latent TB compared to healthy controls [37]. In accor-
dance with our findings, Singh et al. also describe
decreasing numbers of PD-1 expressing T cells during
therapy. Thus, PD-1 may be potentially used to monitor
host immunity among patients with TB during treatment
[36].
In the present study, we also assessed Mtb-specific
proliferative responses of CD4+ and CD8+ T cells, as they
are reported to be impaired in patients with active TB
compared to latent TB and may serve as a biomarker of TB
disease [38, 39]. In our cohort, Mtb-specific CD4+ T cells
proliferation was transiently reduced after 8 weeks of
treatment, which coincides with the early reduction of
bacterial load during the initial phase of treatment, and
may thus reflect efficient treatment. At end of treatment
however, the proliferative responses were again comparable
to baseline values. This observation is in accordance with
findings of Day et al. who did not detect any evidence of
restoration of CFP-10/ESAT-6-specific CD4+ or CD8+ T
cell proliferative capacity, even in subjects evaluated up to
12 months after diagnosis and successful completion of TB
treatment [11]. However, others have described improved
cellular responses in patients with TB following effective
chemotherapy [10]. These contrasting findings might be
explained by different patient population, methodology
and variability of T cell responses due to the use of
different antigens [10, 40]. The implication for the
individual patient is hard to assess. Still, even though
some T cell functions are not completely restored after
successful TB treatment, it is assumed that recurrence of
active disease after effective treatment is mainly caused by
reinfection [41] or associated with immunosuppression [41,
42]. This may indicate that the functional restoration of
memory effector T cells is at least partially effective and
probably depends on a complex orchestration of the
immune system.
Active TB is characterized by a relative depression of
Th1 type cytokines and overproduction and/or enhanced
effect of immunosuppressive molecules such as TGF-b
and IL-10 [14, 43–45]. Immunotherapy in TB has
gained renewed interest with the emergence and spread
of drug resistant and extensively drug resistant TB [46],
and experimental animal models have demonstrated
effect of these strategies [47]. It has been argued that
the presence of IL-10 producing T cells might result in
sustained survival of the infectious organisms and that
methods to reverse this Mtb-induced anergy should be
investigated as an integral part of TB treatment
strategies [44].
On this background, we studied the effects mediated by
blocking of the IL-10/TGF-b pathway on Mtb-induced
proliferation, cytokine production and T cell regulation
during TB treatment. Given that Mtb antigens induce a
predominance of these inhibitory cytokines, we expected
reinforced proliferation and secretion of proinflammatory
cytokines [48, 49]. However, no such effects were observed
throughout the treatment period. Instead, we found a
significant decrease in levels of Mtb-stimulated Tregs after
blocking IL-10/TGF-b, but only at baseline and not later
Figure 5 Blocking of IL-10/TGF-b pathway affects in vitro expansion of Tregs. Fraction of T regulatory cells (CD4+CD25highCD127low) in patients with
TB (N = 16) at different time points of anti-TB treatment. (A) Unstimulated (white bars) and ESAT-6 (hatched bars)-stimulated PBMCs. (B) ESAT-6-
stimulated PBMCs with (hatched) or without (grey) IL-10/TGF-b blocking mAbs. Values in (B) were calculated by subtracting background responses in
corresponding unstimulated controls. Box-whisker plots are shown with median, IQR and minimum/maximum values. P-values were calculated by Mann–
Whitney U-test for group-wise comparison and by Wilcoxon’s matched-pairs test for dependent variables. PBMC, peripheral blood mononuclear cell.
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during TB treatment. To our knowledge, this has not been
previously described. IL-10 has been shown to play a
primary role in the generation of Tregs in vitro [50]. In
animal models, rapid expansion of different Treg subsets
has caused a decline in early immune responses and failure
in achieving clearance of Mtb [51], while depletion of
FoxP3+ cells has been associated with reduction of bacterial
load in mice [52]. Our findings support the notion that the
IL-10 and/or TGF-b pathway upregulates the Treg
compartment in active TB disease.
In accordance with our recent report where Tregs in
blood were analysed in another cohort of active patients
with TB [12], we again observed an initial but transient
increase in CD25highCD127low Tregs during effective TB
treatment. This might be due to a transient redistribution
of redundant Tregs from local sites of infection to
peripheral blood in response to reduced bacterial load
during TB therapy, as supported by animal models [53]. It
may also reflect increased expansion of Tregs as a response
to generalized immune activation during TB, which might
persist for up to several months [54]. Similar patterns were
also found for the CD147+ Tregs, a marker expressed on a
highly suppressive and activated subset of human Tregs
[55]. As the Tregs immune suppressive effect may hamper
mycobacterial eradication [56], interventions that lead to
early downregulation and enhanced Th1 responses might
accelerate disease resolution. Future studies should address
the effect of strategies that target Tregs, as well as the IL-
10/TGF-b pathway, to evaluate their potential adjuvant
use in TB treatment regimens.
The limitation of this study is the small sample size
which increases the risk of type II statistical errors.
Secondly, the heterogeneous patient population consisting
of both PTB and EPTB could potentially influence upon
data. However, when looking at these patient groups
separately, no differences could be found in the various
immune markers. Thirdly, only patients with active TB
were included; hence, we have not been able to compare
our findings with healthy individuals or in patients with
latent TB. Finally, we did not use FoxP3 as a Treg
marker or analysed functional parameters as cytokine
production due to limited number of cells. However, we
have recently shown a significant decline in the fraction of
Mtb-specific IFN-c producing T cells after 2 weeks of
treatment in a comparable cohort of patients with TB
[12].
In conclusion, a transient increase in CD4+ Tregs
together with decreased expression of CD38/HLA-DR
and CD-38/PD-1 on both CD4+ and CD8+ T cells was
found during the course of effective TB therapy,
regardless of TB localization. In addition, our data
suggest that the IL-10/TGF-b pathway may upregulate
the Treg compartment during Mtb antigen stimulation.
Thus, one may speculate whether early inhibition of
Tregs followed by an immune enhancement might favour
a more rapid clearance of Mtb.
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